Archives: Search / 2019 / 2018 / 2017 / 2016 / 2015 / 2014 / 2013 / 2012 / 2011 / 2010
Feb 6, 2019 - Recent 17 Product Launches Contributed $40 Million of Net Sales in Fiscal 2019 YTD Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 second quarter ended December 31, 2018. "Stellar sales across our product offering drove our strong fiscal... More |
Feb 6, 2019 Product Launches, Cost Savings, Insulin Glargine
|
Jan 30, 2019 Lannett Company, Inc. (NYSE: LCI) today announced that it will report financial results for its fiscal 2019 second quarter on Wednesday, February 6, 2019, after the market closes. Lannett... More |
Jan 22, 2019 Company Has Begun Marketing Entacapone IR Tablets Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with a strategic alliance partner to be the exclusive U.S. distributor of Trientine Hydrochloride Capsules,... More |
Dec 11, 2018 --Company Expects to be Well within Its Financial Covenants through the Maturity Date of the Term A Loans-- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an amendment of its credit agreement effecting the term A loans thereunder (Term A Loans) to provide the company greater... More |
Dec 5, 2018 Lannett Company, Inc. (NYSE: LCI) today announced that the company will present at the BMO Capital Markets 2018 Prescription for Success Healthcare Conference on December 12, 2018 at 2:40 p.m.... More |
Nov 12, 2018 --Lannett Locks in $50 Million of Gross Profit for 16-Week Period-- Lannett Company, Inc. (NYSE: LCI) today announced that it has entered into an agreement with Amneal Pharmaceuticals, Inc. (Amneal) with regard to Levothyroxine Sodium Tablets USP. Under the... More |
Nov 7, 2018 - Fiscal 2019 First Quarter Net Sales and Adjusted Net Income Ahead of Expectations Lannett Company, Inc. (NYSE: LCI) today reported financial results for its fiscal 2019 first quarter ended September 30, 2018. "For the fiscal 2019 first quarter, net sales and adjusted net income... More |
Nov 7, 2018 Product Launches, Cost Savings
|
Nov 6, 2018 --Company Has Commenced Launch of Clarithromycin and Expects to Begin Marketing Entacapone In Early Calendar Year 2019-- Lannett Company, Inc. (NYSE: LCI) today announced that it has expanded its agreement with Sunshine Lake LLC, the U.S. subsidiary of the HEC Pharm Group (HEC) of China, to be the exclusive... More |